# Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2021-22 Summary of Recommendations

For additional information: MMWR Recomm Rep 2021;70(No. RR-5), at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. This document is available in HTML format at https://www.cdc.gov/flu/professionals/acip/summary/summary-recommendations.htm.

#### **GROUPS RECOMMENDED FOR VACCINATION**

- Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications.
- If vaccine supply is limited, see priority groups for vaccination in the ACIP statement.

#### **TIMING OF VACCINATION**

- Vaccine should be ideally administered by the end of October, but should continue to be offered as long as influenza viruses are circulating locally and unexpired vaccine is available.
- Some children aged 6 months through 8 years require 2 doses of influenza vaccine (Figure, this page). These children should receive their first dose as soon as possible after vaccine becomes available, and the second dose ≥4 weeks later.
- Children needing 1 dose can be vaccinated soon after vaccine becomes available.
- Vaccination soon after vaccine is available may also be considered for pregnant persons in their third trimester.
- For non-pregnant adults, vaccination in July and August should be avoided, even if vaccine is available during these months, unless there is concern that later vaccination might not be possible.

#### APPROVED AGES AND DOSE VOLUMES

- Approved dose volumes vary by age and product. An ageappropriate vaccine should be used at an appropriate dose.
- Intramuscular influenza vaccines (IIV4s and RIV4) and their approved ages and dose volumes are:

-		
Vaccine	Approved Ages	Dose volume
Afluria Quadrivalent	6 through 35 months	0.25 mL
	≥3 years	0.5 mL
Fluarix Quadrivalent	≥6 months	0.5 mL
FluLaval Quadrivalent	≥6 months	0.5 mL
Fluzone Quadrivalent	6 through 35 months	0.25 mL or 0.5 mL
	≥3 years	0.5 mL
Flucelvax Quadrivalent	≥6 months	0.5 mL
Flublok Quadrivalent	≥18 years	0.5 mL
Fluzone High-Dose	≥65 years	0.7 mL
Quadrivalent		
Fluad Quadrivalent	≥65 years	0.5 mL


- If a dose less than the necessary volume is administered and the error is discovered immediately (before the recipient has left the vaccination setting), administer the remaining additional volume needed. Alternatively, if it is difficult to measure the remaining needed volume, or if the error is discovered later (after the recipient has left the vaccination setting), administer a repeat full dose.
- Healthy non-pregnant persons aged 2 through 49 years may alternatively receive 0.2 mL of LAIV4, 0.1 mL per nostril, using the supplied intranasal sprayer (*Table 3*, page 4)

#### **INFLUENZA VACCINATION IN PREGNANCY**

- Persons who are pregnant or who might be pregnant during the influenza season should receive influenza vaccine.
- Any age-appropriate IIV4 or RIV4 may be given in any trimester.
- LAIV4 should not be used during pregnancy but can be used postpartum.

#### NUMBER OF DOSES FOR AGES 6 MONTHS THROUGH 8 YEARS

- Determine the number of doses needed based on child's age at time of first dose of 2021–22 influenza vaccine and number of doses of influenza vaccine received in previous seasons (Figure).
  - O Children in this age group who previously received ≥2 doses of trivalent or quadrivalent influenza vaccine ≥4 weeks apart before July 1, 2021 need 1 dose of 2021-22 influenza vaccine. The two previous doses need not have been received in the same or consecutive influenza seasons.
  - O Children in this age group who have not previously received ≥2 doses of trivalent or quadrivalent influenza vaccine ≥4 weeks apart before July 1, 2021 or whose vaccination history is unknown need 2 doses of 2021-22 influenza vaccine, given ≥4 weeks apart.
- For children aged 8 years who require 2 doses, both doses should be administered even if the child turns age 9 years between dose 1 and dose 2.
- Persons aged ≥9 years need only one dose.



#### ADULTS AGED ≥65 YEARS

- Persons aged ≥65 years may receive any age-appropriate IIV4 or RIV4. Vaccination should not be delayed to find a particular product if an appropriate one is already available.
- Data support greater benefit of HD-IIV3, RIV4, or allV3 relative to standard-dose unadjuvanted IIVs in this age group, but comparisons of these vaccines with one another are limited.
- HD-IIV3, the most well studied, was more effective than IIV3 in a large two-season randomized trial. However, HD-IIV3 and alIV3 have been replaced by HD-IIV4 and alIV4. Data comparing benefits of these newer formulations to standard-dose unadjuvanted IIV4s are limited.

#### VACCINATION OF PERSONS WITH COVID-19

- Persons in isolation for COVID-19 or in quarantine for known or suspected exposures should not be vaccinated if vaccination will pose an exposure risk to others in the vaccination setting.
- For persons who are moderately or severely ill, vaccination should be deferred until they have recovered. Moderate or severe acute illness with or without fever is a general precaution to vaccination.
- Persons who are mildly ill may be vaccinated; alternatively, vaccination may be deferred until recovery to avoid confusing COVID-19 illness symptoms with post-vaccination reactions.
   PERSONS WITH CHRONIC MEDICAL CONDITIONS
- LAIV4 is not recommended for persons with some chronic medical conditions (*Table 3,* page 4).

### IMMUNOCOMPROMISED PERSONS

- Immunocompromised persons should receive an age-appropriate IIV4 or RIV4. LAIV4 should not be used.
- Immune response might be reduced or minimal in persons on certain medications, chemotherapy, or transplant regimens.
- Timing influenza vaccination relative to a specified period before or after interventions that compromise immunity may be appropriate. The Infectious Diseases Society of America (IDSA) has published guidance concerning the timing of vaccination in relation to such interventions (see *Further Information*, this page).

### CAREGIVERS AND CONTACTS OF HIGH-RISK PERSONS

- Caregivers and contacts (including those of immunosuppressed persons) may receive any age-appropriate IIV4 or RIV4.
- LAIV4 may be given to caregivers and contacts of persons who are not severely immunocompromised (i.e., who do not require a protected environment).
- Health care personnel or hospital visitors who receive LAIV4 should avoid providing care for severely immunosuppressed persons who require a protected environment for 7 days after vaccination.

### PERSONS WITH EGG ALLERGY

- Persons who have experienced only hives after exposure to egg may receive any licensed, recommended influenza vaccine appropriate for their age and health status (i.e., IIV4, RIV4, or LAIV4).
- Persons reporting symptoms other than hives after exposure to egg (such as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention) may also receive any licensed, recommended influenza vaccine that is otherwise appropriate.
  - If a vaccine other than ccIIV4 or RIV4 is selected, it should be administered in an inpatient or outpatient medical setting, supervised by a health care provider who can recognize and manage severe allergic reactions.

### PREVIOUS SEVERE ALLERGIC REACTIONS TO INFLUENZA VACCINES

- Previous severe allergic reaction (e.g., anaphylaxis) to any influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of any valency) is a contraindication to all egg-based IIV4s and LAIV4.
- Previous severe allergic reaction to ccIIV of any valency or to any component of ccIIV4 is a contraindication to ccIIV4. Previous severe allergic reaction to any other influenza vaccine (any egg-based IIV, RIV, or LAIV of any valency) is a precaution to ccIIV4.
- Previous severe allergic reaction to RIV of any valency or any component of RIV4 is a contraindication to RIV4. Previous severe allergic reaction to any other influenza vaccine (any egg-based IIV, ccIIV, or LAIV of any valency) is a precaution to RIV4.
- Each vaccine is also contraindicated for those with a history of severe allergic reaction to any component of that vaccine (other than egg).
- See *Table 3* and *Table 4* on page 4 for more information. VACCINATION ISSUES FOR TRAVELERS
- Travelers who wish to reduce risk for influenza should consider vaccination, preferably ≥2 weeks before departure.
- Persons at higher risk for complications of influenza who were not vaccinated during the preceding fall or winter should consider influenza vaccination before departure, if planning to travel to the tropics, with organized tourist groups, on cruise ships, or to the Southern Hemisphere during April-September.
- Southern Hemisphere influenza vaccines might differ in viral composition from Northern Hemisphere formulations.
- Vaccination with Southern Hemisphere influenza vaccine prior to Southern Hemisphere travel may be reasonable; however, these formulations are generally not available in the U.S.

# VACCINATION AND INFLUENZA ANTIVIRAL MEDICATIONS

- IIV4 and RIV4 may be administered to persons receiving influenza antiviral medications.
- Influenza antivirals might reduce effectiveness of LAIV4, if given before or after LAIV4. Persons who receive influenza antivirals during the following periods should be revaccinated with an age-appropriate IIV4 or RIV4 (intervals may be longer in conditions where medication clearance is delayed):

Influenza Antiviral	Estimated window for potential LAIV interference (based upon half-life reported in package insert)
Oseltamivir and Zanamivir	48 hours before to 2 weeks after LAIV4
Peramivir	5 days before to 2 weeks after LAIV4
Baloxavir	17 days before to 2 weeks after LAIV4

#### ADMINISTRATION OF INFLUENZA VACCINES WITH OTHER VACCINES

- IIV4s and RIV4 may be administered concurrently or sequentially with other live or inactivated vaccines.
- Providers should refer to current CDC/ACIP recommendations and guidance for the use of COVID-19 vaccines for up to date information on administration of these vaccines with other vaccines.
- Injectable vaccines given simultaneously should be administered at separate anatomic sites.
- LAIV4 may be administered simultaneously with other inactivated or live vaccines. If not given simultaneously, then ≥4 weeks should pass between administration of LAIV4 and another live vaccine.
- Immunogenicity and safety of simultaneous or sequential administration of two vaccines containing non-aluminum adjuvants has not yet been evaluated.

### VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)

- VAERS is the national vaccine safety monitoring system comanaged by CDC and FDA which serves as an early warning system to detect possible safety problems with U.S. vaccines.
- Health care providers are required to report to VAERS any adverse event listed by the vaccine manufacturer as a contraindication to further doses of vaccine and adverse events listed here: <u>https://vaers.hhs.gov/docs/VAERS\_Table\_of\_Reportable\_Events\_Following\_Vaccination.pdf</u>
- For information on how to report to VAERS, go the VAERS website at <u>https://vaers.hhs.gov</u>

### FURTHER INFORMATION

### CDC Influenza Information (for more, call 800-232-4636)

- General influenza page: <u>www.cdc.gov/flu</u>
- FluView (weekly U.S. surveillance): <u>www.cdc.gov/flu/weekly</u>
- Influenza Antiviral Guidance: https://www.cdc.gov/flu/professionals/antivirals/summary -clinicians.htm
- COVID-19 vaccination recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vaccspecific/covid-19.html
- Vaccine Storage and Handling Toolkit: <u>https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/</u> <u>index.html</u>

### American Academy of Pediatrics (AAP) Guidance:

https://redbook.solutions.aap.org/selfserve/sspage.aspx?selfservec ont entid=influenza-resources

IDSA Guidance for vaccination of immunocompromised hosts: https://academic.oup.com/cid/article/58/3/e44/336537

Manufacturer package inserts for U.S.-licensed vaccines:

https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccineslicensed- use-united-states

12-10-21

# Available Influenza Vaccines, Age indications, and Administration: 2021-22 Influenza Season

Γrade name Manufacturer	Available presentations	Approved age indications	Volume per dose by age group
Quadrivalent IIVs (IIV4s)—Stand	ard-dose—Egg-based (15 µg H	A per virus component in 0.5 mL; 7.	5 μg HA per virus component in 0.25 mL)
Afluria Quadrivalent Seqirus	0.25 mL prefilled syringe 0.5 mL prefilled syringe 5.0 mL multidose vial*	6 through 35 mos ≥3 yrs ≥6 mos (needle/syringe) 18 through 64 yrs (jet injector)	6 through 35 mos—0.25 mL ≥3 yrs—0.5 mL
Fluarix Quadrivalent GlaxoSmithKline	0.5 mL prefilled syringe	≥6 mos	≥6 mos—0.5 mL
FluLaval Quadrivalent GlaxoSmithKline	0.5 mL prefilled syringe	≥6 mos	≥6 mos—0.5 mL
Fluzone Quadrivalent Sanofi Pasteur	0.5 mL prefilled syringe 0.5 mL single-dose vial 5.0 mL multidose vial*	≥6 mos ≥6 mos ≥6 mos	6 through 35 mos—0.25 mL <b>or</b> 0.5 mL ≥3 yrs—0.5 mL
Quadrivalent IIV (ccIIV4)—Stand	ard-dose—Cell culture-based	(15 µg HA per virus component in 0.	5 mL)
Flucelvax Quadrivalent Seqirus	0.5 mL prefilled syringe 5.0 mL multidose vial*	≥6 mos ≥6 mos	≥6 mos—0.5 mL
Quadrivalent IIV (HD-IIV4)—High	n-dose—Egg-based (60 µg HA	per virus component in 0.7 mL)	
Fluzone High-Dose Quadrivalent Sanofi Pasteur	0.7 mL prefilled syringe	≥65 yrs	≥65 yrs—0.7 mL
Adjuvanted quadrivalent IIV4 (al	IIV4)—Standard-dose with MF	- 59 adjuvant—Egg-based (15 μg HA p	per virus component in 0.5 mL)
Fluad Quadrivalent Seqirus	0.5 mL prefilled syringe	≥65 yrs	≥65 yrs—0.5 mL
Quadrivalent RIV (RIV4)—Recom	nbinant HA (45 μg HA per viru	s component in 0.5 mL)	
Flublok Quadrivalent Sanofi Pasteur	0.5 mL prefilled syringe	≥18 yrs	≥18 yrs—0.5 mL

- IIVs and RIV4 are administered intramuscularly (IM). For adults and older children, the deltoid is the preferred site. For infants and younger children, the anterolateral thigh is the preferred site. Detailed guidance for administration sites and needle length is available in the Best Practice Guidelines of the Advisory Committee on Immunization Practices (ACIP) at <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>
- Afluria Quadrivalent is licensed for IM administration via the Pharmajet Stratis jet injector for ages 18 through 64 years only.
- RIV4 is licensed for persons aged ≥18 years and should not be used for children and adolescents aged <18 years.

Table 2: Live Attenuated Inf	luenza Vaccine (LAIV4)		
Trade name Manufacturer	Available presentations	Approved age indication	Volume per dose
Quadrivalent LAIV (LAIV4)—E	gg-based (contains 10 <sup>6.5-7.5</sup> fluorescent fo	cus units/0.2 mL)	
FluMist Quadrivalent AstraZeneca	0.2 mL prefilled single-use intranasal sprayer	2 through 49 yrs	0.1 mL each nostril (0.2 mL total)

### Administration of LAIV4

- LAIV4 is administered intranasally using the supplied prefilled, single-use sprayer containing 0.2 mL of vaccine.
  - $\circ \quad {\sf Half of the total sprayer contents is sprayed into the first nostril while the recipient is in the upright position.}$
  - $\circ$   $\;$  The attached divider clip is removed and the second half of the dose administered into the other nostril.
- If the vaccine recipient sneezes immediately after administration, the dose should not be repeated.
- If nasal congestion is present that might interfere with delivery of the vaccine to the nasopharyngeal mucosa, deferral should be considered, or another age-appropriate vaccine should be administered

Table	3: Influenza Vaccine Contraindications and P	recautions			
Egg-	Contraindications:				
based		vlaxis) to any component of the v	accine (other than egg) or to	a previous dose of any	
IIV4s	influenza vaccine (any egg-based IIV, ccIIV, RIV	, or LAIV of any valency).			
	Precautions:				
	<ul> <li>Moderate or severe acute illness with or with</li> </ul>	out fever.			
	• History of Guillain-Barré syndrome within 6 w		ie.		
ccIIV4					
	<ul> <li>History of severe allergic reaction (e.g., anaph</li> </ul>	iylaxis) to ccllV of any valency, or	to any component of ccIIV4.		
	Precautions:				
	<ul> <li>Moderate or severe acute illness with or without fever.</li> </ul>				
			-		
	<ul> <li>History of Guillain-Barré syndrome within 6 we</li> </ul>	•			
	<ul> <li>History of severe allergic reaction to a previou</li> </ul>	is dose of any other influenza vaco	cine (any egg-based IIV, RIV,	or LAIV of any valency).	
RIV4	Contraindications:				
	• History of severe allergic reaction (e.g., anaph	vlaxis) to RIV of any valency or to	any component of RIV/		
		ylaxis) to hiv of any valency, of to	any component of MV4		
	Precautions:				
	<ul> <li>Moderate or severe acute illness with or with</li> </ul>				
	<ul> <li>History of Guillain-Barré syndrome within 6 we</li> </ul>	eeks of receipt of influenza vaccin	e		
	History of severe allergic reaction to a previou	s dose of any other influenza vac	cine (any egg-based IIV, ccIIV	. or LAIV of any valency).	
LAIV4				,	
2/1/1/4					
	<ul> <li>History of severe allergic reaction (e.g., anaph</li> </ul>		accine (other than egg) or to	a previous dose of any	
	influenza vaccine (i.e, any egg-based IIV, ccIIV,	, RIV, or LAIV of any valency).			
	Concomitant aspirin or salicylate-containing the second seco		ς		
	<ul> <li>Children aged 2 through 4 years who have rec</li> </ul>			port that a boalth care	
		-			
	provider has told them during the preceding 1	.2 months that their child had whe	eezing or asthma or whose m	nedical record indicates a	
	wheezing episode has occurred during the pre	ceding 12 months			
	Children and adults who are immunocompron	-	but not limited to medication	ns, congenital or acquired	
	immunodeficiency states, HIV infection, anato				
	<ul> <li>Close contacts and caregivers of severely imm</li> </ul>	unosuppressed persons who requ	uire a protected environment	t	
	Pregnancy				
	<ul> <li>Persons with active communication between the second second</li></ul>	the CSE and the oronharvny naso	nharvny nose or ear or any	other cranial CSE leak	
	<ul> <li>Persons with cochlear implants (due to potent</li> </ul>	tial for CSF leak, which might exist	; for some period of time afte	er implantation. Providers	
	Persons with cochlear implants (due to potential for CSF leak, which might exist for some period of time after implantation. Providers				
	might consider consultation with a specialist c	oncerning risk of persistent CSF le	eak if an age-appropriate inac		
	-	oncerning risk of persistent CSF le	eak if an age-appropriate inac		
	vaccine cannot be used).			ctivated or recombinant	
	<ul><li>vaccine cannot be used).</li><li>Receipt of influenza antiviral medication withi</li></ul>	n the previous 48 hours for oselta	amivir and zanamivir, 5 days f	ctivated or recombinant	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i></li> </ul>	n the previous 48 hours for oselta	amivir and zanamivir, 5 days f	ctivated or recombinant	
	<ul><li>vaccine cannot be used).</li><li>Receipt of influenza antiviral medication withi</li></ul>	n the previous 48 hours for oselta	amivir and zanamivir, 5 days f	ctivated or recombinant	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> </ul>	n the previous 48 hours for oselta antiviral medications, page 2, for a	amivir and zanamivir, 5 days f	ctivated or recombinant	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <i>Precautions:</i></li> <li>Moderate or severe acute illness with or without the severe acute a</li></ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a	amivir and zanamivir, 5 days f additional guidance).	ctivated or recombinant	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <i>Precautions:</i></li> <li>Moderate or severe acute illness with or witho</li> <li>History of Guillain-Barré syndrome within 6 within 6</li></ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a	amivir and zanamivir, 5 days f additional guidance).	ctivated or recombinant	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> </ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a put fever eeks of receipt of influenza vaccin	amivir and zanamivir, 5 days f additional guidance). Ie	ctivated or recombinant for peramivir, and 17 days	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <i>Precautions:</i></li> <li>Moderate or severe acute illness with or witho</li> <li>History of Guillain-Barré syndrome within 6 within 6</li></ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a put fever eeks of receipt of influenza vaccin	amivir and zanamivir, 5 days f additional guidance). Ie	ctivated or recombinant for peramivir, and 17 days	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 with</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that mighting the syndrome within a syndrome within the medication of the syndrome within the syndrome within</li></ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a put fever eeks of receipt of influenza vaccin nt predispose to complications fro	amivir and zanamivir, 5 days f additional guidance). ne om influenza (e.g., chronic pu	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a put fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta	amivir and zanamivir, 5 days f additional guidance). e pm influenza (e.g., chronic pu abolic disorders [including dia	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus])	
Table	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul>	n the previous 48 hours for oselta Intiviral medications, page 2, for a put fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta	amivir and zanamivir, 5 days f additional guidance). e pm influenza (e.g., chronic pu abolic disorders [including dia	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus])	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or within 6 with thistory of Guillain-Barré syndrome within 6 with Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li>4: Contraindications and Precautions for Personal syndrome syndrom</li></ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a but fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta sons with a History of Severe J	amivir and zanamivir, 5 days f additional guidance). Me om influenza (e.g., chronic pu abolic disorders [including dia Allergic Reaction to an Inf	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus])	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li>4: Contraindications and Precautions for Persaccine (of any valency) associated with previous</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a but fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta sons with a History of Severe J	amivir and zanamivir, 5 days f additional guidance). e pm influenza (e.g., chronic pu abolic disorders [including dia	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus])	
	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or within 6 with thistory of Guillain-Barré syndrome within 6 with Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li>4: Contraindications and Precautions for Personal syndrome syndrom</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a out fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta sons with a History of Severe / Available	amivir and zanamivir, 5 days f additional guidance). The pom influenza (e.g., chronic pu abolic disorders [including dia Allergic Reaction to an Inf 2 2021–22 influenza vaccines	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus])	
V s	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li><b>4: Contraindications and Precautions for Pers</b></li> <li>accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <u>sons with a History of Severe /</u> <u>Available</u> <u>Egg-based IIV4s and LAIV4</u>	amivir and zanamivir, 5 days f additional guidance). ne om influenza (e.g., chronic pu abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines ccllV4	tivated or recombinant for peramivir, and 17 days lmonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4	
V s A	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 was</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that might [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persona accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a put fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta sons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication*	amivir and zanamivir, 5 days f additional guidance). The pm influenza (e.g., chronic pu abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution <sup>+</sup>	tivated or recombinant for peramivir, and 17 days lmonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution†	
V s A	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persaccine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> Contraindication* Contraindication*	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication*	ctivated or recombinant for peramivir, and 17 days Ilmonary, cardiovascular abetes mellitus]) Fluenza Vaccine RIV4 Precaution† Precaution†	
V S A A	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe History of Guillain-Barré syndrome within 6 w.</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> <li><b>4: Contraindications and Precautions for Pers</b></li> <li>accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV</li> <li>ny RIV</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> Contraindication* Contraindication*	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication* Precaution†	tivated or recombinant for peramivir, and 17 days lmonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution†	
V S A A	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persaccine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> Contraindication* Contraindication*	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication*	ctivated or recombinant for peramivir, and 17 days Ilmonary, cardiovascular abetes mellitus]) Fluenza Vaccine RIV4 Precaution† Precaution†	
V s A A U	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persona accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny RIV</li> <li>nknown influenza vaccine</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> Contraindication* Contraindication* Contraindication* Allergist	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication* Precaution† consultation recommended	ctivated or recombinant for peramivir, and 17 days Ilmonary, cardiovascular abetes mellitus]) Fluenza Vaccine RIV4 Precaution† Precaution† Contraindication*	
×When	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perservations (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny RIV</li> <li>nknown influenza vaccine</li> <li>a contraindication is present, a vaccine should not</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a put fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication to to	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus]) Fluenza Vaccine RIV4 Precaution† Precaution† Contraindication*	
*When read	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 with</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persons accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny RIV</li> <li>nknown influenza vaccine</li> <li>na contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each it tion (e.g., anaphylaxis) to any component of that vaccine</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta isons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist is be administered. In addition to t individual influenza vaccine is con accine. Vaccine components can b	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A	Imonary, cardiovascular abetes mellitus]) Iuenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic ohave had a severe allergic Nthough a history of severe	
*Whee read aller	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li><b>4: Contraindications and Precautions for Pers</b></li> <li>accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny clIV ny ny RIV inknown influenza vaccine in a contraindication is present, a vaccine should not tion (e.g., anaphylaxis) to any component of that was give reaction (e.g., anaphylaxis) to egg is a labeled component of that was give reaction (e.g., anaphylaxis) to egg is a labeled component of that was give reaction (e.g., anaphylaxis) to egg is a labeled component of that was give reaction (e.g., anaphylaxis) to egg is a labeled component of that was give reaction (e.g., anaphylaxis)</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta isons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist is be administered. In addition to t individual influenza vaccine is con accine. Vaccine components can b	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines cclIV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A	Imonary, cardiovascular abetes mellitus]) Iuenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic ohave had a severe allergic Nthough a history of severe	
A A A U *Whee read read aller aller	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persent accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny clIV ny RIV influenza vaccine</li> <li>na contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each is tion (e.g., anaphylaxis) to any component of that vagic reaction (e.g., anaphylaxis) to egg is a labeled cogy to egg (see Persons with Egg Allergy, page 2).</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta sons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can b portraindication to the use of egg-b	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines CollV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r	ctivated or recombinant for peramivir, and 17 days Imonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic b have had a severe allergic b have had b have have have have have have have have	
*Whee allee †Whee	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perse accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny clIV influenza vaccine is present, a vaccine should not tion to influenza vaccine is not contraindication is present, a vaccine should not tion (e.g., anaphylaxis) to any component of that vacgic reaction (e.g., anaphylaxis) to egg is a labeled cc gy to egg (see Persons with Egg Allergy, page 2).</li> </ul>	n the previous 48 hours for oselta <i>intiviral medications</i> , page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications fro neurologic, hematologic, or meta <b>sons with a History of Severe /</b> <b>Available</b> <b>Egg-based IIV4s and LAIV4</b> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication*</u> <u>Contraindication to tindividual influenza vaccine is con faccine. Vaccine components can b pontraindication to the use of egg-bally be deferred but might be indice</u>	amivir and zanamivir, 5 days f additional guidance). The second	tivated or recombinant for peramivir, and 17 days lmonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution† Precaution† Precaution† Contraindication* on history of severe allergic have had a severe allergic have had a severe allergic bave had a severe allergic have had a severe allergic bave had a severe allergic have had a severe allergic	
*Whee reac allee *Whee	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b> <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perserations (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny cclIV ny RIV influenza vaccine na contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each it in (e.g., anaphylaxis) to any component of that was gic reaction (e.g., anaphylaxis) to egg is a labeled cc gy to egg (see <i>Persons with Egg Allergy</i>, page 2).</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin and predispose to complications from neurologic, hematologic, or meta sons with a History of Severe A Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can b pontraindication to the use of egg-b ally be deferred but might be indic n consider using the following vac	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines ccIIV4 Precaution† Contraindications Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r cated if the benefit of protect coines in these instances; how	Imonary, cardiovascular abetes mellitus]) Iuenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic have had a severe allergic bave had a severe allergic Nthough a history of severe makes an exception for	
*Whee read allee allee tWhee occt	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b></li> <li>Moderate or severe acute illness with or withe History of Guillain-Barré syndrome within 6 w.</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> <li><b>4: Contraindications and Precautions for Persona accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</b></li> <li>ny egg-based IIV or LAIV ny ccIIV ny RIV Influenza vaccines noted in the Table, each it tion (e.g., anaphylaxis) to any component of that vagig reaction (e.g., anaphylaxis) to egg is a labeled cc gy to egg (see <i>Persons with Egg Allergy</i>, page 2).</li> <li>na precaution is present, vaccination should generation is present, vaccination. Providers caar in an inpatient or outpatient medical setting with</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin ant predispose to complications from neurologic, hematologic, or meta sons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can b bontraindication to the use of egg-b ally be deferred but might be indic in consider using the following vac supervision by a health care prov	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inflet 2021–22 influenza vaccines CollV4 Precaution† Contraindication* Precaution† Consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r cated if the benefit of protect cocines in these instances; how rider who is able to recognize	Imonary, cardiovascular abetes mellitus]) Iuenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic though a history of severe nakes an exception for tion from the vaccine wever, vaccination should and manage severe allergic	
*Whee read allee tWhee read allee couth occorread	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 with</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persons aged-based IIV or LAIV ny cclIV or LAIV ny cclIV ny clIV or LAIV ny cclIV ny RIV influenza vaccine not component of that vagic reaction (e.g., anaphylaxis) to any component of that vagic reaction (e.g., anaphylaxis) to egg is a labeled cc gy to egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generatively to restore with a history of severe allergient and the previous and the</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin ant predispose to complications from neurologic, hematologic, or meta sons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication * Contraindication to the individual influenza vaccine is con accine. Vaccine components can bo portraindication to the use of egg-b and the following vac supervision by a health care provide the following vac the following v	amivir and zanamivir, 5 days f additional guidance). The point influenza (e.g., chronic pur abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines ccllV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP re- cated if the benefit of protect ccines in these instances; how page based IIV or LAIV of ar	Imonary, cardiovascular abetes mellitus]) Iduenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic o have had a severe allergic Nthough a history of severe makes an exception for tion from the vaccine wever, vaccination should e and manage severe allergic y valency, the provider can	
*When reac allen twhen contro occurreac contro	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persaccine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny RIV influenza vaccine na contraindication is present, a vaccine should not tion to influenza vaccine na contraindication is present, a vaccine should not tion (e.g., anaphylaxis) to egg is a labeled corgy to egg (see Persons with Egg Allergy, page 2).</li> <li>na precaution is present, vaccination should generations: 1) for persons with a history of severe allergic cell with cordian is present.</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications from neurologic, hematologic, or meta sons with a History of Severe 4 Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can be bontraindication to the use of egg-to the administered but might be indiced n consider using the following vacous supervision by a health care prover c reaction (e.g., anaphylaxis) to art th a history of severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction the addition of the use of the severe allergic reaction (a.g. anaphylaxis) to art the addition of the use of the severe allergic reaction (a.g. anaphylaxis) to art the addition of the use of the severe allergic reaction (a.g. anaphylaxis) the addition of the use of the severe allergic reaction (a.g. anaphylaxis) the addition of the use of the severe allergic reaction (a.g. anaphylaxis) the addition of the use of the severe allergic reaction (a.g. anaphylaxis) the addition of the use of the severe allergic reaction (a.g. anaphylaxis) the addition (a.g. anaphylaxis) th	amivir and zanamivir, 5 days f additional guidance). The second	tivated or recombinant for peramivir, and 17 days [monary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution† Precaution† Precaution† Contraindication* on history of severe allergic have had a severe allergic have had bave have have have have have have have h	
*Whee read allee twhee read cont cont prov	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perse accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny ccIIV ny RIV influenza vaccine na contraindication is present, a vaccine should not tion to influenza vaccine na contraindication is present, a vaccine should not tion (e.g., anaphylaxis) to egg is a labeled cc giv egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generative is the risk for an adverse reaction. Providers call r in an inpatient or outpatient medical setting with tions: 1) for persons with a history of severe allergi with risk for an adverse reaction. Providers call r in an inpatient or outpatient medical setting with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with ti</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a pout fever eeks of receipt of influenza vaccin int predispose to complications frome neurologic, hematologic, or meta isons with a History of Severe 1 Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Allergist is be administered. In addition to to naccine. Vaccine components can b bontraindication to the use of egg-based undividual influenza vaccine is con accine. Vaccine components can bontraindication to the use of egg-based intraindication to the use o	amivir and zanamivir, 5 days f additional guidance). The second	Imonary, cardiovascular abetes mellitus]) Imonary, cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular Mitous) Imonary (cardiovascular Imonary (ca	
*Whee reac allee tWhee outvocco reac con prov vale	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b> <ul> <li>Moderate or severe acute illness with or withde</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persers</li> <li>accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny RIV Inknown influenza vaccine not on fluenza vaccine should not tion to influenza vaccines noted in the Table, each it tion (e.g., anaphylaxis) to any component of that vacgic reaction (e.g., anaphylaxis) to egg is a labeled cc gy to egg (see <i>Persons with Egg Allergy</i>, page 2). In a precaution is present, vaccination should generations in present, or outpatient medical setting with tions: 1) for persons with a history of severe allerging ccIIV4 or RIV4; 2) for persons with a mistering RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a mistering ccIIV4 or RIV4; and 3) for persons with a misterin</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a pout fever eeks of receipt of influenza vaccin int predispose to complications frome neurologic, hematologic, or meta isons with a History of Severe 1 Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Allergist is be administered. In addition to to naccine. Vaccine components can b bontraindication to the use of egg-based undividual influenza vaccine is con accine. Vaccine components can bontraindication to the use of egg-based intraindication to the use o	amivir and zanamivir, 5 days f additional guidance). The second	Imonary, cardiovascular abetes mellitus]) Imonary, cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular Mitous) Imonary (cardiovascular Imonary (ca	
*Whee reac allee tWhee outvocco reac con prov vale	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migl [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perse accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny ccIIV ny RIV influenza vaccine na contraindication is present, a vaccine should not tion to influenza vaccine na contraindication is present, a vaccine should not tion (e.g., anaphylaxis) to egg is a labeled cc giv egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generative is the risk for an adverse reaction. Providers call r in an inpatient or outpatient medical setting with tions: 1) for persons with a history of severe allergi with risk for an adverse reaction. Providers call r in an inpatient or outpatient medical setting with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with tions: 1) for persons with a history of severe allergi with ti</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications from neurologic, hematologic, or meta sons with a History of Severe 1 Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can b bontraindication to the use of egg-b ally be deferred but might be indic n consider using the following vac supervision by a health care prove c reaction (e.g., anaphylaxis) to ar th a history of severe allergic reac rsons with a history of severe allergic reac rsons with a history of severe allergic reac	amivir and zanamivir, 5 days f additional guidance). The second	Imonary, cardiovascular abetes mellitus]) Imonary, cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular abetes mellitus]) Imonary (cardiovascular Mitous) Imonary (cardiovascular Imonary (ca	
*Whee reac allee twhee cont prov vale com	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perse accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny ccIIV ny ccIIV ny clIV inknown influenza vaccine in a contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each it it in to influenza vaccines noted in the Table, each it is present, vaccination should generating yo to egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generating is present, vaccination should generating is present, and in previous ever allergic reaction (e.g., anaphylaxis) to end you egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generating is present, and in patient or outpatient medical setting with itons: 1) for persons with a history of severe allergic ider administering ccIIV4 or RIV4; 2) for persons with a precaution. Provider can consider administering ccIIV4 ponent is responsible for the allergic reaction.</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin and predispose to complications from neurologic, hematologic, or meta sons with a History of Severe 1 Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication* Contraindication to the individual influenza vaccine is con accine. Vaccine components can bo ontraindication to the use of egg-th IIIV be deferred but might be indic n consider using the following vac supervision by a health care prove creaction (e.g., anaphylaxis) to ar th a history of severe allergic reace rsons with a history of severe allergic reace rsons with a history of severe allergic reace Providers can also consider cons	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines ccllV4 Precaution† Contraindication* Precaution† consultation recommended the contraindication based of traindicated for persons who crated if the benefit of protect coises in these instances; how ider who is able to recognize ty egg-based IIV or LAIV of ar titon (e.g., anaphylaxis) to an rgic reaction (e.g., anaphylax ulting with an allergist to hel	ctivated or recombinant for peramivir, and 17 days (Imonary, cardiovascular abetes mellitus]) (Imonary, cardiov	
*When reac allen twhen occor reac con prov vale com	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see Vaccination and influenza a Precautions: <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Perse accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny ccIIV ny ccIIV ny clIV ny RIV influenza vaccine in the Table, each it tion (e.g., anaphylaxis) to egg is a labeled cgy to egg (see Persons with Egg Allergy, page 2). In a precaution is present, vaccination should generations: 1) for persons with a history of severe allergis cell valuency and years of severe allergis cell valuency and the set of gy to egg constrained administering RIV4; and 3) for persons with a distory of severe allergis cell valuency administering ccIIVA or RIV4; 2) for persons with a severe allergis cell valuency administering ccIIVA or RIV4; 2) for persons with a persons wi</li></ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a pout fever eeks of receipt of influenza vaccin nt predispose to complications from neurologic, hematologic, or meta sons with a History of Severe 4 Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Allergist is be administered. In addition to to individual influenza vaccine is con accine. Vaccine components can be bontraindication to the use of egg-to the bit of the severe allergic reac reaction (e.g., anaphylaxis) to are th a history of severe allergic reac rsons with a history of severe allergic reac rsons with a history of severe allergic reactors VACCINE ABBREVIATIONS rletters indicate valency	amivir and zanamivir, 5 days f additional guidance). The second	tivated or recombinant for peramivir, and 17 days [Imonary, cardiovascular abetes mellitus]) fluenza Vaccine RIV4 Precaution† Precaution† Precaution† Contraindication* on history of severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should e and manage severe allergic to nave had a severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should e and manage severe allergic to any valency, the is) to any RIV of any p determine which vaccine	
*Whee read aller aller aller aller outv occi read con prov vale com	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b> <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 we</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li>4: Contraindications and Precautions for Persent accine (of any valency) associated with previous evere allergic reaction (e.g., anaphylaxis)</li> <li>ny egg-based IIV or LAIV ny cclIV ny RIV influenza vaccines noted in the Table, each it iton (e.g., anaphylaxis) to any component of that was give reaction is present, a vaccine should not tion to influenza vaccines noted in the Table, each if iton (e.g., anaphylaxis) to any component of that was give reaction is present, vaccination should generation is present, and anaphylaxis) to experiment or outpatient medical setting with tions: 1) for persons with a history of severe allergisider administering cclIV4 or RIV4; 2) for persons with an inpatient or outpatient medical setting with tions: 1) for persons with a history of severe allergis ider administering cclIV4 or RIV4; 2) for persons with a nonstering cclIV4 ponent is responsible for the allergic reaction.</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin int predispose to complications from neurologic, hematologic, or meta isons with a History of Severe 1 Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist ibe administered. In addition to the individual influenza vaccine is contraindication to the use of egg-b accine. Vaccine components can bo bontraindication to the use of egg-b ally be deferred but might be indice in consider using the following variation (e.g., anaphylaxis) to ard th a history of severe allergic reactions VACCINE ABBREVIATIONS rietters indicate valency of influenza viruses represented):	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf 2021–22 influenza vaccines ccllV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r cated if the benefit of protect ccines in these instances; how ider who is able to recognize by egg-based IIV or LAIV of ar stion (e.g., anaphylaxis) to an rgic reaction (e.g., anaphylaxis) to hel Prefixes are sometimes used to a for adjuvanted IIV (e.g.	Imonary, cardiovascular abetes mellitus]) iluenza Vaccine RIV4 Precaution† Precaution† Contraindication* on history of severe allergic though a history of severe makes an exception for tion from the vaccine wever, vaccination should e and manage severe allergic Nthough a history of severe makes an exception for tion from the vaccine wever, vaccination should e and manage severe allergic y valency, the provider can y ccllV of any valency, the is) to any RIV of any p determine which vaccine	
*Whee read aller aller aller aller contread contread contread vale contread contread provivale contread provivale contread provivale contread south outh outh outh outh outh outh outh	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b> <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 with</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li><b>4: Contraindications and Precautions for Personal excere allergic reaction (e.g., anaphylaxis)</b></li> <li>ny egg-based IIV or LAIV</li> <li>ny ccIIV</li> <li>nknown influenza vaccine</li> <li>na contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each it tion (e.g., anaphylaxis) to any component of that vac gic reaction (e.g., anaphylaxis) to egg is a labeled core gy to egg (see <i>Persons with Egg Allergy</i>, page 2).</li> <li>na precaution is present, vaccination should generations in present, vaccination should generations in a contraindication contraindication should and the tions: 1) for persons with a history of severe allergic ider administering ccIIV4 or RIV4; 2) for persons witider can consider administering ccIIV4 ponent is responsible for the allergic reaction.</li> <li><i>fluenza vaccine types:</i></li> <li><i>Numerals after</i></li> <li><i>L</i> Inactivated Influenza Vaccine</li> <li><i>A</i> for quasing the responsibile for the allergic reaction.</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin and predispose to complications from neurologic, hematologic, or meta sons with a History of Severe / Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Contraindication* Allergist be administered. In addition to t individual influenza vaccine is con accine. Vaccine components can b pontraindication to the use of egg-b III be deferred but might be indic in consider using the following vac supervision by a health care prov c reaction (e.g., anaphylaxis) to ard th a history of severe allergic reac rsons with a history of severe allergic reac rsons with a history of severe allergic reac sons with a history of severe allergic reac VACCINE ABBREVIATIONS r letters indicate valency of influenza viruses represented): drivalent vaccines	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf e 2021–22 influenza vaccines ccllV4 Precaution† Contraindications based of the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r cated if the benefit of protect ccines in these instances; how ider who is able to recognize ny egg-based IIV or LAIV of ar tion (e.g., anaphylaxis) to an rgic reaction (e.g., anaphylax ulting with an allergist to hel <b>Prefixes are sometimes used to</b> a for adjuvanted IIV (e.g. cc for cell culture-based	Imonary, cardiovascular abetes mellitus]) Iuenza Vaccine RIV4 Precaution† Precaution† Precaution† Contraindication* On history of severe allergic Nave had a severe allergic Nave had a severe allergic Nave had a severe allergic Nave had a severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should and manage severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should and manage severe allergic to any RIV of any p determine which vaccine refer specifically to certain IIVs: , alIV4) IIV (e.g., ccIIV4)	
*Whee read read read read aller aller aller aller contr outv occu read contr outv occu read contr outv occu read contr outv outv occu read aller	<ul> <li>vaccine cannot be used).</li> <li>Receipt of influenza antiviral medication withi for baloxavir (see <i>Vaccination and influenza a</i> <b>Precautions:</b> <ul> <li>Moderate or severe acute illness with or withe</li> <li>History of Guillain-Barré syndrome within 6 with</li> <li>Asthma in persons aged ≥5 years</li> <li>Other underlying medical conditions that migh [except isolated hypertension], renal, hepatic,</li> </ul> </li> <li><b>4: Contraindications and Precautions for Personal excere allergic reaction (e.g., anaphylaxis)</b></li> <li>ny egg-based IIV or LAIV</li> <li>ny ccIIV</li> <li>nknown influenza vaccine</li> <li>na contraindication is present, a vaccine should not tion to influenza vaccines noted in the Table, each it tion (e.g., anaphylaxis) to any component of that vac gic reaction (e.g., anaphylaxis) to egg is a labeled core gy to egg (see <i>Persons with Egg Allergy</i>, page 2).</li> <li>na precaution is present, vaccination should generations in present, vaccination should generations in a contraindication contraindication should and the tions: 1) for persons with a history of severe allergic ider administering ccIIV4 or RIV4; 2) for persons witider can consider administering ccIIV4 ponent is responsible for the allergic reaction.</li> <li><i>fluenza vaccine types:</i></li> <li><i>Numerals after</i></li> <li><i>L</i> Inactivated Influenza Vaccine</li> <li><i>A</i> for quasing the responsibile for the allergic reaction.</li> </ul>	n the previous 48 hours for oselta intiviral medications, page 2, for a but fever eeks of receipt of influenza vaccin int predispose to complications from neurologic, hematologic, or meta isons with a History of Severe 1 Available Egg-based IIV4s and LAIV4 Contraindication* Contraindication* Contraindication* Allergist ibe administered. In addition to the individual influenza vaccine is contraindication to the use of egg-b accine. Vaccine components can bo bontraindication to the use of egg-b ally be deferred but might be indice in consider using the following variation (e.g., anaphylaxis) to ard th a history of severe allergic reactions VACCINE ABBREVIATIONS rietters indicate valency of influenza viruses represented):	amivir and zanamivir, 5 days f additional guidance). me abolic disorders [including dia Allergic Reaction to an Inf 2021–22 influenza vaccines ccllV4 Precaution† Contraindication* Precaution† consultation recommended the contraindications based of traindicated for persons who be found in package inserts. A based IIV4s and LAIV4, ACIP r cated if the benefit of protect ccines in these instances; how ider who is able to recognize by egg-based IIV or LAIV of ar stion (e.g., anaphylaxis) to an rgic reaction (e.g., anaphylaxis) to hel Prefixes are sometimes used to a for adjuvanted IIV (e.g.	Imonary, cardiovascular abetes mellitus]) Imonary, cardiovascular abetes mellitus]) Imenza Vaccine RIV4 Precaution† Precaution† Precaution† Contraindication* On history of severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should and manage severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should and manage severe allergic Nathough a history of severe makes an exception for tion from the vaccine wever, vaccination should and manage severe allergic to any RIV of any p determine which vaccine refer specifically to certain IIVs: , aIIV4) IIV (e.g., ccIIV4) , HD-IIV4)	

4